Consensus Rhythm Pharmaceuticals, Inc.

Equities

RYTM

US76243J1051

Real-time Estimate Cboe BZX Other stock markets 02:20:46 2024-04-24 pm EDT			5-day change	1st Jan Change
39.96 ^USD	-0.11%		+4.51%	-12.58%

Apr. 18	Wells Fargo Trims Price Target on Rhythm Pharmaceuticals to $52 From $53, Maintains Overweight Rating	MT
Apr. 01	Rhythm Pharmaceuticals to Sell $150 Million in Series A Convertible Preferred Stock	MT

Evolution of the average Target Price on Rhythm Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

af16234dec37c5d.Dv1o8YpRhIAPqrwmpPmNIYzt68s3_lNLz8I6L-QA70w.a6o_huIVw9Y45-Rc4Y7cSu-Up65BrxkN-7V1SNVrmSM3i1yT_Sj08GvliA~a9c720c900c102a99e9f94ad6f1ff291

Analyst Recommendations on Rhythm Pharmaceuticals, Inc.

Wells Fargo Trims Price Target on Rhythm Pharmaceuticals to $52 From $53, Maintains Overweight Rating	Apr. 18	MT
Rhythm Pharmaceuticals Insider Sold Shares Worth $735,600, According to a Recent SEC Filing	Mar. 22	MT
Rhythm Pharmaceuticals Insider Sold Shares Worth $707,005, According to a Recent SEC Filing	Mar. 22	MT
Rhythm Pharmaceuticals Insider Sold Shares Worth $608,498, According to a Recent SEC Filing	Mar. 20	MT
Rhythm Pharmaceuticals Insider Sold Shares Worth $627,520, According to a Recent SEC Filing	Mar. 20	MT
Rhythm Pharmaceuticals Insider Sold Shares Worth $608,498, According to a Recent SEC Filing	Mar. 20	MT
Rhythm Pharmaceuticals Insider Sold Shares Worth $608,498, According to a Recent SEC Filing	Mar. 20	MT
Rhythm Pharmaceuticals Insider Sold Shares Worth $608,498, According to a Recent SEC Filing	Mar. 20	MT
Goldman Sachs Raises Price Target on Rhythm Pharmaceuticals to $52 From $42, Maintains Buy Rating	Jan. 25	MT
Needham Raises Price Target on Rhythm Pharmaceuticals to $50 From $45, Maintains Buy Rating	Jan. 04	MT
Morgan Stanley Upgrades Rhythm Pharmaceuticals to Overweight From Equalweight, Raises Price Target to $55 From $29	Dec. 19	MT
Wells Fargo Raises Rhythm Pharmaceuticals Price Target to $53 From $48, Maintains Overweight Rating	Dec. 19	MT
Goldman Sachs Raises Price Target on Rhythm Pharmaceuticals to $42 From $38, Maintains Buy Rating	Dec. 07	MT
Needham Raises Rhythm Pharmaceuticals Price Target to $45 From $32, Maintains Buy Rating	Dec. 07	MT
Morgan Stanley Adjusts Rhythm Pharmaceuticals' Price Target to $29 From $28, Keeps Equalweight Rating	23-10-10	MT
BofA Securities Upgrades Rhythm Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $27 From $22	23-08-02	MT
Goldman Sachs Raises Rhythm Pharmaceuticals' Price Target to $45 From $40, Maintains Buy Rating	23-03-02	MT
Canaccord Genuity Adjusts Price Target on Rhythm Pharmaceuticals to $56 From $52, Keeps Buy Rating	23-03-02	MT
Morgan Stanley Adjusts Price Target on Rhythm Pharmaceuticals to $28 From $26, Keeps Equalweight Rating	23-03-02	MT
Goldman Sachs Raises Rhythm Pharmaceuticals' Price Target to $40 From $35, Maintains Buy Rating	23-01-26	MT
Canaccord Genuity Assumes Coverage on Rhythm Pharmaceuticals at Buy With $52 Price Target	23-01-18	MT
Morgan Stanley Adjusts Price Target on Rhythm Pharmaceuticals to $26 From $16, Maintains Equal-Weight Rating	22-11-09	MT
Goldman Sachs Adjusts Rhythm Pharmaceuticals' Price Target to $31 from $28, Maintains Buy Rating	22-09-07	MT
Goldman Sachs Upgrades Rhythm Pharmaceuticals to Buy From Neutral; Price Target is $28	22-08-08	MT
BofA Securities Upgrades Rhythm Pharmaceuticals to Neutral From Underperform, Adjusts Price Target to $20 From $8	22-08-05	MT